A:

Government regulation lengthens the process for bringing new pharmaceuticals to market and restricts the drugs sector to protect public safety. Governments create incentives for particular behaviors and encourage the development of safe and effective drugs. Pharmaceutical companies are heavily regulated to ensure they are in compliance with federal safety laws. In the United States, the Food and Drug Administration (FDA) ensures that new drugs are rigorously tested for safety, efficacy and minimal side effects.

As a result of this testing, most new drugs are researched and investigated for 10 to 15 years before they are brought to market. Drugs must undergo human trials that are intended to discover potential side effects and treatment efficacy. At any point in the multi-phase testing process, new drugs may fail to show effectiveness or may have unreasonable side effects. If either of these occurs, the company may research it further in the lab at its own expense but will not receive permission to release it to the market until the product yields positive results in human trials.

Throughout this period of research and development, pharmaceutical companies must have dependable sources of financing. Typically, this financing is in the form of either investments and loans or revenue from sales of other products. Government regulation gives a distinct competitive advantage to companies large enough to maintain secure funding. Major drug manufacturers with profitable products already in the market usually do not require the ongoing fundraising and venture capital that startups do.

This process is a significant barrier to entry in the pharmaceutical industry. As a result, mergers and acquisitions (M&As) are common. New companies and larger companies both benefit from mergers. Big companies take advantage of opportunities to acquire profitable new products and small companies benefit from the financial boost and expertise of a large partner. Because of the regulatory expense, companies have a strong incentive to offer support to only the most promising drugs. M&As usually happen only after new drugs begin to show promise in trials.

Some drugs benefit from additional government incentives. Orphan drugs receive special consideration from the FDA in order to encourage pharmaceutical companies to develop treatments for rare diseases. Incentives for the development of orphan drugs include quicker approval time and potential financial assistance for development. Companies are often permitted to charge substantial prices for orphan drugs, making them more profitable than they would be without government intervention. As a result, the development of orphan drugs continues to grow at a faster rate than the development of traditional pharmaceuticals.

Overall, government regulation of the drug sector has resulted in a longer, more-expensive product development process that favors treatments for rare illnesses. All approved drugs have been rigorously tested by the FDA to protect consumers from harmful or ineffective treatments. This process is designed to occur over a long period of time to ensure that only the safest and most effective drugs arrive on the market.

RELATED FAQS
  1. What are the primary risks associated with investing in the drugs sector?

    Learn more about the primary risks facing investors in the pharmaceutical and biotechnology industries. Find out how regulation ... Read Answer >>
  2. What is the drugs sector?

    Learn more about the drug industry and how new drugs are brought to market. Find out about how drug research is financed ... Read Answer >>
  3. What process does a company need to follow to bring a new drug to market?

    Learn about the costly price of bringing new drugs to market. Discover why the pharmaceutical industry invests billions of ... Read Answer >>
  4. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
  5. What are the primary factors that drive share prices in the drugs sector?

    Learn about the primary factors that drive share prices in the drug sector. Creating and manufacturing drugs is a complex ... Read Answer >>
  6. What factors make the drug sector good for value investing?

    Discover what makes the drugs sector good for value investing. The perfect ingredient for value investors is to find undervalued ... Read Answer >>
Related Articles
  1. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn more about how pharmaceutical companies price drugs, why prices are often very high and why it can be difficult to settle on a suitable price.
  2. Investing

    3 of America's Most Expensive Drugs and Who Profits From Them

    Learn about orphan drugs that are some of the most expensive drugs in America. Read about the companies that manufacture these drugs.
  3. Investing

    It's No Accident That Drugs Are Expensive

    Branded drugs are expensive in large part because it's expensive and risky to develop them
  4. Investing

    Using DCF In Biotech Valuation

    Valuing firms in this sector can seem like a black art, but there is a systematic way to pin a price on potential.
  5. Investing

    Drug Approvals Fell to Six-Year Low in 2016

    New drug approvals dropped to modest levels in 2016 following highs in 2014 and 2015.
  6. Investing

    Drug Prices: Name Brands Doubled in Last 5 Years (ESRX)

    Express Scripts' Drug Trends Report, released Monday, revealed that the average price of brand name drugs rose 16.2% in 2015, with over one third of brand name drugs seeing price increases over ...
  7. Insurance

    Big Pharma: Will Price Pressure Happen No Matter What?

    Watch out for a possible decline in pharmaceutical stock prices, thanks to a renewed debate about the role of government policy and macroeconomic headwinds.
  8. Investing

    PJP: PowerShares Dynamic Pharmaceuticals ETF

    Learn about the PowerShares Dynamic Pharmaceuticals exchange-traded fund, which specializes on investing in pharmaceutical companies.
  9. Investing

    Drug Giants May Benefit From China Drug Inclusion

    Pharma giants may see higher sales as the Chinese government subsidizes expensive prescription drugs.
  10. Investing

    Cost of Old Cancer Drugs Rises in EU Amid Outcry

    The prices of several off-patent cancer drugs have soared more than 100% in Europe.
RELATED TERMS
  1. Orphan Drug Credit

    A federal tax credit that provides an incentive for pharmaceutical ...
  2. Orphan Drug

    A drug or biological product that treats a rare condition or ...
  3. Drug

    A substance that cures, treats, prevents or reduces the symptoms ...
  4. Abbreviated New Drug Application (ANDA)

    A written request to the U.S. Food and Drug Administration to ...
  5. Food And Drug Administration - FDA

    A government agency established in 1906 with the passage of the ...
  6. New Drug Application (NDA)

    The final step formally taken by a drug sponsor, wherein it applies ...
Hot Definitions
  1. Asset Allocation

    An investment strategy that aims to balance risk and reward by apportioning a portfolio's assets according to an individual's ...
  2. IRR Rule

    A measure for evaluating whether to proceed with a project or investment. The IRR rule states that if the internal rate of ...
  3. Short Covering

    Short covering is buying back borrowed securities in order to close an open short position.
  4. Covariance

    A measure of the degree to which returns on two risky assets move in tandem. A positive covariance means that asset returns ...
  5. Liquid Asset

    An asset that can be converted into cash quickly and with minimal impact to the price received. Liquid assets are generally ...
  6. Nostro Account

    A bank account held in a foreign country by a domestic bank, denominated in the currency of that country. Nostro accounts ...
Trading Center